Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma, accounting for 30-40% of all newly diagnosed lymphomas. DLBCL is considered a heterogeneous disease, with some specific clinicopathological variants of DLBCLs being associated with the presence of the EBV.
1 EBV is a lymphotropic virus that has been implicated in the development of several lymphoid malignancies, mainly Burkitt lymphoma (BL) and Hodgkin's lymphoma and with low prevalence in DLBCL.
1 BCL6 is a key transcriptional repressor during normal B-cell differentiation that has been shown to repress NF-kB in some DLBCLs. 2 In some B-cell lymphomas, BCL6 expression was inversely correlated with LMP1 expression, and some evidences suggest that LMP1 can cause downregulation of BCL6 (ref. 3) , but other possible mechanisms have not been studied. We have found a strong inverse correlation between BCL6 protein expression and EBV infection (Po0.001, Figures 1a and b) in a series of 149 DLBCL samples, where only one out of 34 EBV-positive cases (2.94%) expressed BCL6, although 87 out of 115 EBV-negative cases expressed BCL6 (75.65%). However, this correlation was independent of LMP1 because 54% of EBER-positive samples were LMP1-negative (Spearman, P-value: 0.18). Little is known about the mechanisms that cause the absence of BCL6 in EBVpositive DLBCL; however, the possibility that EBV-encoded miRNAs could contribute to BCL6 repression has never been explored.
We have studied the miRNA expression profile in 36 DLBCL samples using miRNA microarrays. Prevalence of EBV in this series (33 EBV-negative and 3 EBV-positive) was close to normal prevalence in DLBCL.
1 Twenty-two out of thirty-two analysed viral miRNAs were significantly upregulated in EBV-positive samples (4two-fold change; t-test corrected P-valueo0.05, Figure 1c , Supplementary table 2 and Supplementary table 3) . None of the miRNAs belonged to the BHRF1 cluster, a finding that confirms previous results suggesting that the highest levels of these miRNAs are reached during the lytic cycle. 4 To test the hypothesis that some of these miRNAs can potentially downregulate BCL6, we made a bioinformatic prediction using the miRanda algorithm. This prediction indentified 21 binding sites in the 3 0 UTR of BCL6 for 18 EBV-encoded miRNAs (Supplementary table 1) . More than 70% of these predictions were also found with other algorithms (Supplementary Figure 1) . Ten of these miRNAs were also differentially expressed between EBV-positive and EBV-negative DLBCL cases. This high proportion of miRNAs potentially targeting BCL6 suggests a physiological mechanism of the virus to reduce the amount of BCL6. Consequently, we selected four EBV-encoded miRNAs for further validation. These miRNAs were selected according to the following parameters: 1) attainment of a high score from miRanda and 2) differential expression in the EBV-positive DLBCL cases. In this way, we selected ebv-miR-BART3, ebv-miR-BART9 and ebv-miR-BART17-5p. We also selected ebv-miR-BART7 because, although it does not achieve one of the highest scores from miRanda, the program predicts two binding sites for the miRNA in the 3 0 UTR of BCL6, increasing the probability of it being a bona fide regulator of BCL6 (Supplementary Figure 2) . To analyse these miRNAs in a larger series of cases, we selected 40 cases (15 EBV-positive and 25 EBV-negative) from the 149-patients series to check their expression by RT-PCR. The mean of the viral miRNAs expression among EBER-positive patients was 10-to 100-fold higher compared with EBER-negative patients (Figure 1d ). We also analysed EBV-encoded miRNA levels by RT-PCR in BL and DLBCL-derived cell lines and observed a correlation between BCL6 protein and miRNA levels (Figures 1e and f) . These results indicate that a relatively low level of expression of these miRNAs could enable the high level of expression of BCL6 observed in EBV-positive BL, 5 thus explaining the differences between BL and DLBCL.
Therefore, to validate the putative BCL6-regulatory role of these miRNAs, we transfected synthetic miRNAs and measured the luciferase activity in a reporter system in which we cloned the 3 0 UTR of BCL6 (Supplementary Materials & methods) . With this approach, we noted a significant reduction in luciferase signal for three of the four viral miRNAs assayed (Figure 2a ) when compared with either the reporter transfected with a miRNA mimic negative control sequence or the vector without the 3 0 UTR of BCL6. Ebv-miR-BART3, ebv-miR-BART9 and ebvmiR-BART17-5p reduced the luciferase signal by at least 60%. The effect of these miRNAs on the endogenous BCL6 protein was investigated in lymphoid EBV-negative BCL6-expressing cell lines. We used three DLBCL-derived cell lines (DB, SU-DHL-4 and SU-DHL-6) and one BL-derived cell line (Ramos) to test the effect of these miRNAs in different lymphoid models. In DLBCL-derived cell lines transfection of the viral miRNAs ebvmiR-BART3, ebv-miR-BART9 and ebv-miR-BART17-5p led to a reduction in the levels of BCL6 protein ranging from 25 to 72%, 48 h after transfection ( Figure 2b ). In contrast, ebv-miR-BART7 was able to reduce BCL6 protein expression only in SU-DHL-4 and SU-DHL-6 whereas it had little or no effect in DB. In Ramos cell line, transfection of the miRNAs led to a significant reduction of BCL6 protein levels in the case of ebv-miR-BART7, ebv-miR-BART9 and ebv-miR-BART17-5p, whereas the cells showed no response to ebv-miR-BART3. This may reflect a cell context-dependent phenomenon that could be related to targetsite accessibility. Moreover, we used EBV-positive DLBCLderived cell lines to allow inhibition of endogenous EBVencoded miRNAs by miRNA inhibitors. Inhibition of ebv-miR-BART9 and ebv-miR-BART17-5p, led to a moderate increase in the expression of BCL6 in the Farage cell line but not in the DoHH-2 cell line, which expressed the highest levels of EBVencoded miRNAs (Figure 2c ).
EBV is more frequently found in tumors with a plasmablastic phenotype in which other factors (for example, expression of BLIMP1) could be repressing BCL6 at the transcriptional level. Our data support a role of EBV microRNAs that could help to diminish BCL6 expression facilitating BCL6 transcriptional repression by BCL6 targets such as BLIMP1.
7 However, the reason by which EBV downregulates BCL6 in DLBCL remains unknown. It is known that several EBV-driven lymphomas rely on the activation of the NF-kB pathway 8 as well as ABC-type DLBCL.
9 Viral proteins such as LMP1 and LMP2A can activate the NF-kB pathway directly or indirectly to promote the survival of the host cell.
8,10-12 Because BCL6 represses NF-kB under normal and pathogenic conditions, 2 BCL6 downregulation may be necessary to promote survival of the EBV-positive neoplastic cells in some DLBCLs. EBV does not repress BCL6 in Burkitt lymphoma; however, in this tumor type, activation of the NF-kB pathway has been shown to induce apoptosis, 13 and so the role of the virus might be different in this disease. 
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Leukemia ( The risk of cancers of varied tissues is increased in persons who are overweight or obese. [1] [2] [3] [4] The increased relative risk (RR) of cancer in overweight and obese subjects has also included the hematological malignancies, although the major types of leukemia and lymphoma have not been stratified in several of these large epidemiological studies.
1,2,5-7 Myeloma also has been associated with overweight and obesity as has its antecedent, essential monoclonal gammopathy. 8, 9 The evidence for an increased risk of leukemia in the aggregate 1,2,5-7 and of the four major types of leukemia is noteworthy.
10 Given the broad range of tissues for which a risk of neoplasia is increased in overweight and obese persons, there appears to be a global effect of the metabolic, endocrinologic and inflammatory changes resulting from obesity on either the induction of neoplastic clones, or the selection and enhanced growth and survival of preexisting, dormant transformed clones.
BCR-ABL-positive chronic myelogenous leukemia is a very uncommon secondary leukemia. Unlike secondary acute myelogenous leukemia, which can occur as a result of exposure to high-dose ionizing radiation, certain types of chemotherapy (especially, alkylating agents and topoisomerase inhibitors), prolonged inhalation of tobacco smoke or higher-dose prolonged exposure to benzene, only ionizing radiation is an established cause of secondary chronic myelogenous leukemia.
11 In addition, there is little evidence that either a familial predisposition gene (non-syndromic) or an inherited predisposing disorder (syndromic predisposition gene) is associated with chronic myelogenous leukemia, as it is with acute myelogenous leukemia.
11 Although a proportion of the healthy population carries low copy numbers of the BCR-ABL oncogene in its blood cells, it is not known whether these clones are susceptible to clonal evolution to a clinically overt neoplasm, either spontaneously or under provocation. The apparent effect of increased fat mass on an increased RR of chronic myelogenous leukemia should be of research interest to students of carcinogenesis and leukemogenesis. The relationship of overweight to cancer is a major challenge to the practice of preventive medicine and the soft (cajoling) and hard (pharmacotherapy) science of behavior modification.
In a search of the literature, I have identified eight studies that have examined the relationship of overweight or obesity to the risk of chronic myelogenous leukemia, either as a primary research effort or as a meta-analysis of prior studies. In these studies, the body mass index (BMI) was used as a measure of fat tissue mass. ). The HR was higher for chronic than acute myelogenous leukemia, but the number of cases of chronic myelogenous leukemia was not sufficient to apply statistical tests of homogeneity between the two leukemias.
12
In a study of 2 000 611 Norwegian men and women, reported in 2006, the trend of RR of chronic myelogenous leukemia using a normal range of BMI of 18.5-24.9 kg/m 2 as the referent value (1.0), and studying degrees of BMI from underweight, to normal, to overweight, to obese, to massively obese, found a significant trend for increased risk of chronic myelogenous leukemia from RR ¼ 0.78 in underweight (BMIo18.5 kg/m 2 ) to RR ¼ 1.65 in obese men (BMIX30.0 kg/m 2 ). 13 In women, the same significant trend was observed ranging from RR ¼ 0.85 in underweight women to a RR ¼ 1.89 in women with Class III obesity (BMIX40 kg/m 2 ). The results were ambiguous in that the trends by BMI were highly significant and the RR of chronic myelogenous leukemia increased generally with increased BMI; however, the increased RR at each level of increased BMI was not statistically significant in several cases.
Three reports between 2004 and 2007 found an increased RR of chronic myelogenous leukemia in overweight or obese men of European or African descent, 14 and in men and women, 13, 15 but the RR (1.15 to 1.65) was either not significant or just missed statistical significance. However, a meta-analysis, published in 2008, of the three studies, 13-15 which included five populations, found a significantly increased meta-relative risk (MRR) of chronic myelogenous leukemia (MRR ¼ 1.26 (95% CI, 1.09-1.46)) in the obese study subjects as compared with those with a normal BMI.
10
In a population-based case-control study conducted in eight Canadian provinces, published in 2005, an association was found with increased BMI and an increased RR of chronic myelogenous leukemia with a significant dose-response relationship; the increment in risk for chronic myelogenous leukemia from normal to overweight (odds ratio (OR) ¼ 1.4; 95% CI, 1.0-2.0) and from normal to obese (OR ¼ 2.3; 95% CI, 1.5-3.4) subjects was highly significant. 16 Overweight and obesity and the risk of hematological malignancies were studied in a cohort of Swedish and Finnish twins (70 067 persons), who were followed prospectively. An increased RR of chronic myelogenous leukemia was observed in those who were overweight or obese (RR ¼ 2.5 95% CI, 1.0-6.2).
